Active substance
Results for the substance brentuximab vedotin
1 result
About this active substance
Brentuximab vedotin is a medication used for the treatment of certain types of lymphoma, including relapsed or refractory Hodgkin's lymphoma and anaplastic large cell lymphoma. It is an antibody-drug conjugate that targets the CD30 protein on cancer cells, destroying them.
The medication is administered via intravenous infusion, usually once every few weeks, as directed by a doctor. The treatment requires close monitoring to assess the patient's response and manage potential side effects.
Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts. In rare cases, severe adverse effects such as tumor lysis syndrome or serious infections may occur.
Brentuximab vedotin is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
The medication is administered via intravenous infusion, usually once every few weeks, as directed by a doctor. The treatment requires close monitoring to assess the patient's response and manage potential side effects.
Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts. In rare cases, severe adverse effects such as tumor lysis syndrome or serious infections may occur.
Brentuximab vedotin is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.